Genta has finally put an end to the long and troubled development of its investigational antisense therapy Genasense for melanoma. While Harold Camping is just the latest in a series of false prophets predicting the end of the world, Genasense observers who had predicted the demise of the compound since before its first phase III melanoma failure back in 2004 have now been proved right.
The end really is nigh for Genasense in melanoma
Genta has finally put an end to the long and troubled development of its investigational antisense therapy Genasense for melanoma. While Harold Camping is just the latest in a series of false prophets predicting the end of the world, Genasense observers who had predicted the demise of the compound since before its first phase III melanoma failure back in 2004 have now been proved right.
More from Anticancer
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.